Journal of Nuclear Cardiology

, Volume 23, Issue 3, pp 560–569 | Cite as

Prognostic value of heart rate response during regadenoson stress myocardial perfusion imaging in patients with end stage renal disease

  • Wael AlJaroudi
  • Tania Campagnoli
  • Ibtihaj Fughhi
  • Marwan Wassouf
  • Amjad Ali
  • Rami Doukky
Original Article



Blunted heart rate response (HRR) to vasodilator stress agents is associated with worse outcomes. There are limited data assessing the effect of impaired HRR to regadenoson among patients with end-stage renal disease (ESRD) undergoing stress myocardial perfusion imaging (MPI).


We prospectively followed patients with ESRD enrolled in the ASSUAGE and ASSUAGE-CKD trials. HRR was defined as 100*(peak stress heart rate-resting heart rate)/resting heart rate. Study cohort was dichotomized to blunted and normal HRR groups according to an established median HRR value <28% or ≥28%, which were propensity-score matched based on 22 clinical and imaging covariates. The Primary endpoint was all-cause death. The secondary cardiac-specific endpoints included: (1) the composite endpoint of cardiac death or myocardial infarction; (2) the composite endpoint of cardiac death, myocardial infarction, or late (>90 days) coronary revascularization.


There were 303 patients followed for 35 ± 10 months. In the entire cohort, there was a stepwise increase in the rates of death and all secondary endpoints with worsening HRR (P values ≤.001). Blunted HRR (<28%) was associated with increased risk of death (unadjusted hazard ratio 4.10 [1.98-8.46], P < .001) and all secondary endpoints (P ≤ .001). After multivariate adjustment, HRR remained an independent predictor of mortality and secondary endpoints whether used as continuous or dichotomous variable, and added incremental prognostic value for all-cause death (P = .046). Blunted HRR was associated with increased event rate among patients with normal myocardial perfusion (P = .001) and abnormal perfusion (P = .053). In the propensity-matched cohort of 132 patients (66 in each group), blunted HRR was associated with significant increase in all-cause death (21% vs. 5%, HR 5.09 [1.46-17.7], P=.011), and similarly for the secondary endpoints.


Blunted HRR (<28%) to regadenoson is a strong and independent predictor of death and cardiovascular events in patients with ESRD and adds incremental prognostic value.


Heart rate response regadenoson myocardial perfusion imaging end-stage renal disease prognosis outcome 



Coronary revascularization


End-stage renal disease


Heart rate response


Myocardial infarction


Myocardial perfusion imaging


Summed difference score


Single photon emission computed tomography


Summed rest score


Summed stress score



Rami Doukky serves on the Advisory Board for Astellas Pharma and receives research funding from Astellas Pharma. Other Authors have no conflicts to report.




  1. 1.
    Klocke FJ, Baird MG, Lorell BH, Bateman TM, Messer JV, Berman DS, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging–executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). Circulation 2003;108:1404-18.CrossRefPubMedGoogle Scholar
  2. 2.
    AMR/Arlington Medical Resources Inc. Myocardial Study Market Guide, Jan to Jun 2012; 2012.Google Scholar
  3. 3.
    Astellas Pharma US. Lexiscan. 2015. Accessed 6 July 2015.
  4. 4.
    Dhalla AK, Wong MY, Wang WQ, Biaggioni I, Belardinelli L. Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats. J Pharmacol Exp Ther 2006;316:695-702.CrossRefPubMedGoogle Scholar
  5. 5.
    Hage FG, Heo J, Franks B, Belardinelli L, Blackburn B, Wang W, et al. Differences in heart rate response to adenosine and regadenoson in patients with and without diabetes mellitus. Am Heart J 2009;157:771-6.CrossRefPubMedGoogle Scholar
  6. 6.
    Abidov A, Hachamovitch R, Hayes SW, Ng CK, Cohen I, Friedman JD, et al. Prognostic impact of hemodynamic response to adenosine in patients older than age 55 years undergoing vasodilator stress myocardial perfusion study. Circulation 2003;107:2894-9.CrossRefPubMedGoogle Scholar
  7. 7.
    Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS. A prognostic score for prediction of cardiac mortality risk after adenosine stress myocardial perfusion scintigraphy. J Am Coll Cardiol 2005;45:722-9.CrossRefPubMedGoogle Scholar
  8. 8.
    Mathur S, Shah AR, Ahlberg AW, Katten DM, Heller GV. Blunted heart rate response as a predictor of cardiac death in patients undergoing vasodilator stress technetium-99m sestamibi gated SPECT myocardial perfusion imaging. J Nucl Cardiol 2010;17:617-24.CrossRefPubMedGoogle Scholar
  9. 9.
    Venkataraman R, Hage FG, Dorfman TA, Heo J, Aqel RA, de Mattos AM, et al. Relation between heart rate response to adenosine and mortality in patients with end-stage renal disease. Am J Cardiol 2009;103:1159-64.CrossRefPubMedGoogle Scholar
  10. 10.
    Iqbal FM, Al Jaroudi W, Sanam K, Sweeney A, Heo J, Iskandrian AE, et al. Reclassification of cardiovascular risk in patients with normal myocardial perfusion imaging using heart rate response to vasodilator stress. Am J Cardiol 2013;111:190-5.CrossRefPubMedGoogle Scholar
  11. 11.
    Hage FG, Dean P, Bhatia V, Iqbal F, Heo J, Iskandrian AE. The prognostic value of the heart rate response to adenosine in relation to diabetes mellitus and chronic kidney disease. Am Heart J 2011;162:356-62.CrossRefPubMedGoogle Scholar
  12. 12.
    Bhatheja R, Francis GS, Pothier CE, Lauer MS. Heart rate response during dipyridamole stress as a predictor of mortality in patients with normal myocardial perfusion and normal electrocardiograms. Am Heart J 2005;95:1159-64.Google Scholar
  13. 13.
    Doukky R, Rangel MO, Wassouf M, Dick R, Alqaid A. Morales Demori R. The safety and tolerability of regadenoson in patients with end-stage renal disease: The first prospective evaluation. J Nucl Cardiol 2013;20:205-13.CrossRefPubMedGoogle Scholar
  14. 14.
    Aljaroudi W, Hermann D, Hage F, Heo J, Iskandrian AE. Safety of regadenoson in patients with end-stage renal disease. Am J Cardiol 2010;105:133-5.CrossRefPubMedGoogle Scholar
  15. 15.
    Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002;106:1974-9.CrossRefPubMedGoogle Scholar
  16. 16.
    Ranpuria R, Hall M, Chan CT, Unruh M. Heart rate variability (HRV) in kidney failure: Measurement and consequences of reduced HRV. Nephrol Dial Transpl 2008;23:444-9.CrossRefGoogle Scholar
  17. 17.
    Doukky R, Morales DR, Jain S, Kiriakos R, Mwansa V, Calvin JE. Attenuation of the side effect profile of regadenoson: A randomized double-blinded placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging “The ASSUAGE trial”. J Nucl Cardiol 2012;19:448-57.CrossRefPubMedGoogle Scholar
  18. 18.
    Doukky R, Rangel MO, Dick R, Wassouf M, Alqaid A, Margeta B. Attenuation of the side effect profile of regadenoson: A randomized double-blind placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging and have severe chronic kidney disease—the ASSUAGE-CKD trial. Int J Cardiovasc Imaging 2013;29:1029-37.CrossRefPubMedGoogle Scholar
  19. 19.
    Henzlova MJ, Cerqueira MD, Hansen CL, Taillefer R, Yao SS. ASNC imaging guidelines for nuclear cardiology procedures: Stress protocols and tracers. J Nucl Cardiol 2009;2009:1-13.Google Scholar
  20. 20.
    Ballany W, Mansour K, Morales Demori R, Al-Amoodi M, Doukky R. The impact of regimented aminophylline use on extracardiac radioisotope activity in patients undergoing regadenoson stress SPECT myocardial perfusion imaging: A substudy of the ASSUAGE trial. J Nucl Cardiol 2014;21:496–502.CrossRefPubMedGoogle Scholar
  21. 21.
    Golzar Y, Olusanya A, Pe N, Dua SG, Golzar J, Gidea C, et al. The significance of automatically measured transient ischemic dilation in identifying severe and extensive coronary artery disease in regadenoson, single-isotope technetium-99m myocardial perfusion SPECT. J Nucl Cardiol 2015;22:526-34.CrossRefPubMedGoogle Scholar
  22. 22.
    Doukky R, Frogge N, Bayissa YA, Balakrishnan G, Skelton JM, Confer K, et al. The prognostic value of transient ischemic dilatation with otherwise normal SPECT myocardial perfusion imaging: A cautionary note in patients with diabetes and coronary artery disease. J Nucl Cardiol 2013;20:774-84.CrossRefPubMedGoogle Scholar
  23. 23.
    Hage FG, Dean P, Iqbal F, Heo J, Iskandrian AE. A blunted heart rate response to regadenoson is an independent prognostic indicator in patients undergoing myocardial perfusion imaging. J Nucl Cardiol 2011;18:1086-1094.CrossRefPubMedGoogle Scholar
  24. 24.
    Hage FG, Ghimire G, Lester D, McKay J, Bleich S, El-Hajj S, et al. The prognostic value of regadenoson myocardial perfusion imaging. J Nucl Cardiol 2015. doi: 10.1007/s12350-014-0050-y.Google Scholar
  25. 25.
    Heinze G, Juni P. An overview of the objectives of and the approaches to propensity score analyses. Eur Heart J 2011;32:1704-8.CrossRefPubMedGoogle Scholar
  26. 26.
    Bellam N, Veledar E, Dorbala S, Di Carli MF, Shah S, Eapen D, et al. Prognostic significance of impaired chronotropic response to pharmacologic stress Rb-82 PET. J Nucl Cardiol 2014;21:233-44.CrossRefPubMedGoogle Scholar
  27. 27.
    Hage FG, Wackers FJ, Bansal S, Chyun DA, Young LH, Inzucchi SE, et al. The heart rate response to adenosine: A simple predictor of adverse cardiac outcomes in asymptomatic patients with type 2 diabetes. Int J Cardiol 2013;167:2952-7.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Parikh K, Appis A, Doukky R. Cardiac imaging for the assessment of patients being evaluated for kidney or liver transplantation. J Nucl Cardiol 2015;22:282-96.CrossRefPubMedGoogle Scholar
  29. 29.
    Aggarwal H, AlJaroudi WA, Mehta S, Mannon R, Heo J, Iskandrian AE, et al. The prognostic value of left ventricular mechanical dyssynchrony using gated myocardial perfusion imaging in patients with end-stage renal disease. J Nucl Cardiol 2014;21:739-46.CrossRefPubMedGoogle Scholar
  30. 30.
    AlJaroudi W, Aggarwal H, Venkataraman R, Heo J, Iskandrian AE, Hage FG. Impact of left ventricular dyssynchrony by phase analysis on cardiovascular outcomes in patients with end-stage renal disease. J Nucl Cardiol 2010;17:1058-64.CrossRefPubMedGoogle Scholar
  31. 31.
    Aljaroudi W, Koneru J, Iqbal F, Aggarwal H, Heo J, Iskandrian AE. Left ventricular mechanical dyssynchrony by phase analysis of gated single photon emission computed tomography in end-stage renal disease. Am J Cardiol 2010;106:1042-7.CrossRefPubMedGoogle Scholar

Copyright information

© American Society of Nuclear Cardiology 2015

Authors and Affiliations

  • Wael AlJaroudi
    • 1
  • Tania Campagnoli
    • 2
  • Ibtihaj Fughhi
    • 2
  • Marwan Wassouf
    • 2
  • Amjad Ali
    • 3
  • Rami Doukky
    • 2
    • 4
  1. 1.Division of Cardiovascular MedicineClemenceau Medical CenterBeirutLebanon
  2. 2.Division of CardiologyRush University Medical CenterChicagoUSA
  3. 3.Department of Radiology and Nuclear MedicineRush University Medical CenterChicagoUSA
  4. 4.Division of CardiologyJohn H. Stroger Jr. Hospital of Cook CountyChicagoUSA

Personalised recommendations